Japanese Society of Medical Oncology Clinical Guidelines: RAS ( KRAS / NRAS ) mutation testing in colorectal cancer patients-Reference-Cited by-同舟云学术

Japanese Society of Medical Oncology Clinical Guidelines: RAS ( KRAS / NRAS ) mutation testing in colorectal cancer patients

Published:2015-03 Issue:3 Volume:106 Page:324-327
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Taniguchi Hiroya¹,Yamazaki Kentaro²,Yoshino Takayuki³,Muro Kei¹,Yatabe Yasushi⁴,Watanabe Toshiaki⁵,Ebi Hiromichi⁶,Ochiai Atsushi⁷,Baba Eishi⁸,Tsuchihara Katsuya⁹

Affiliation:

1. Department of Clinical Oncology Aichi Cancer Center Hospital AichiJapan

2. Division of Gastrointestinal Oncology Shizuoka Cancer Center ShizuokaJapan

3. Department of Gastrointestinal Oncology National Cancer Center Hospital East ChibaJapan

4. Department of Pathology and Molecular Diagnostics Aichi Cancer Center Hospital AichiJapan

5. Department of Surgical Oncology Graduate School of Medicine and Faculty of Medicine The University of Tokyo TokyoJapan

6. Division of Medical Oncology Cancer Research Institute Kanazawa University IshikawaJapan

7. Department of Pathology and Clinical Laboratories National Cancer Center Hospital TokyoJapan

8. Department of Comprehensive Clinical Oncology Faculty of Medical Sciences Kyushu University FukuokaJapan

9. Division of Translational Research Exploratory Oncology Research and Clinical Trial Center National Cancer Center Chiba Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12595

Reference10 articles.

1. Japanese Society of Medical Oncology.Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients (1 screen). [Cited 10 Apr 2014.] Available from URL:http://www.jsmo.or.jp/file/dl/newsj/1288.pdf.

2. Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

3. PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

4. K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

5. Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database;British Journal of Cancer;2024-02-24

2. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer;Nature Medicine;2024-02-12

3. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer;JAMA;2023-04-18

4. Chemotherapy-induced Reversion of Mutant RAS to Wild-type RAS in Metastatic Colorectal Cancer;Anticancer Research;2022-04-30

5. Activin A promotes cell proliferation, invasion and migration and predicts poor prognosis in patients with colorectal cancer;Oncology Reports;2022-04-20